Assertio, Bausch say Glumetza doesn't have monopoly over diabetes treatment

MLex Summary: Assertio Therapeutics and Bausch Health told a US judge that purchasers of Glumetza cannot claim they had market power over diabetes treatments, given the number of interchangeable products that...

Already a subscriber? Click here to view full article